Absci (ABSI) Other Non-Current Liabilities (2020 - 2026)
Absci (ABSI) posted Other Non-Current Liabilities of $806000.0 for Q1 2026, down 21.21% sequentially from $1.0 million in Q4 2025, and down 52.17% YoY from $1.7 million in Q1 2025.
Analysis
Absci (ABSI) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Absci has reported Other Non-Current Liabilities for 7 years, with the latest figure at $806000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 52.17% year-over-year to $806000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $806000.0 (down 52.17% YoY) and the FY2025 annual result came in at $1.0 million, up 669.17% from the prior year.
- Other Non-Current Liabilities declined to $806000.0 in Q1 2026 per ABSI's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.8 million in Q3 2025 and troughed at $15000.0 in Q2 2024.
- A 5-year average of $560785.7 and a median of $224500.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities tumbled 99.73% in 2022, then soared 9780.0% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $35000.0 in 2022, then soared by 742.86% to $295000.0 in 2023, then slumped by 54.92% to $133000.0 in 2024, then surged by 669.17% to $1.0 million in 2025, then slipped by 21.21% to $806000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $806000.0, $1.0 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 806,000.00 |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2022 | 35,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 222,000.00 |
| Dec 31, 2021 | 12.16 Mn |
| Sep 30, 2021 | 12.13 Mn |
| Jun 30, 2021 | 18.49 Mn |
| Dec 31, 2020 | 749,000.00 |